ClinicalTrials.gg
CompletedNCT06707155Updated Jun 5, 2025

Digital Tracking With Auto Data Reporting

An observational study in Type 1 Diabetes Mellitus (T1DM), sponsored by Persei Vivarium. Completed at 1 site in Spain. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.

Sponsored by Persei Vivarium · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
25
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain — 25 open to participants now, 30 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · Spain.

Enrollment
33rd of 36
25 · median 170
Started
2024
with 9 others
Observational
36 of 150
8 open now
Registered
120th of 150
by date

Among the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, this one is the 33rd largest by enrollment of the 36 observational ones that give a count, is one of 10 that started in 2024, is one of 36 observational ones, and was the 120th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

25 of the 150 studies in Diabetes Mellitus, Type 1 with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 150 studies in Diabetes Mellitus, Type 1 with a site in Spain, or all of them as a file.
02

Study summary

Type 1 diabetes mellitus is a chronic pathology and represents a constant challenge for children and adolescents with diabetes and their families.

The objective of the treatment of DM1 in pediatric age is to achieve and maintain an optimal glycemic control in order to avoid or delay chronic micro- and macrovascular complications related to the disease.

However, currently, despite technological advances and the development of new insulin formulations, the majority of patients are unable to achieve glycemic goals.

In this context, the use of digital tools/platforms that allow remote monitoring of patients and that facilitate telemedicine have shown potential to improve treatment adherence and facilitate continued therapeutic education, improving clinical results with savings in time and associated costs.

Read the detailed description

Patients are enrolled to a prospective, observational Post-Market clinical Follow-up study. This is a pilot study.

The protocol and informed consent documents have been reviewed and approved by the hospital human subjects reviewboard and the study will be performed in accordance with the Declaration of Helsinki

03

Conditions studied

  • Type 1 Diabetes Mellitus (T1DM)

Keywords

  • T1DM
  • digital platforms
  • Remote patient monitoring
  • glycemic control
  • Caaring
04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients from the Hospital Infantil Universitario Niño Jesús diagnosed with type 1 diabetes mellitus who meet the selection criteria and sign the informed consent will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with type 1 diabetes mellitus
  • Patients treated with subcutaneous insulin in multiple daily doses or patients treated with subcutaneous insulin in continuous subcutaneous infusion systems
  • Patients using a glucose monitoring system
  • Patients who are able to complete the study questionnaires
  • Patients who are able to handle the application on a smart mobile phone.
  • is obtained from the patient.

Exclusion criteria

Exclusion Criteria:

  • Patients who, in the opinion of the investigator will not be able to commit to carrying out the follow-ups or do not have adequate technological skills
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
25 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Potential for improvement of type 1 diabetes through the use of a digital platform

    Percentage of events related to diabetes reported through the use of a digital platform of the total events related to diabetes that occurred between medical visits.

    Time frame: 12 weeks

Secondary outcomes

  1. Degree of completion of data related to treatments between medical visits

    The Degree of completion of data related to treatments between medical is defined as the ratio between the questionnaires requested and completed.

    Time frame: Day 0 up to Week 12

  2. Degree of completion of data related to intercurrent processes between visits

    The Degree of completion by patients of data related to intercurrent processes between is defined as the ratio between the questionnaires requested and completed

    Time frame: Day 0 up to Week 12

  3. Degree of completion of therapeutic adherence between visits

    The Degree of completion of therapeutic adherence by patients between visits is defined as the ratio between the questionnaires requested and completed.

    Time frame: Weekly up to 12 weeks

  4. Change in the patient's quality of life scale

    Change in the patient's quality of life scale the study compared to baseline. Health-Related Quality of Life in children and adolescents: Values (0-100), a higher score reflects a higher health-related quality of life (HRQoL).

    Time frame: Day 0 and week 12

  5. Degree of completion of the questionnaires

    Degree of completion of the questionnaires depending on age and gender, type of treatment and degree of glycemic control

    Time frame: Week 12

  6. Variation in clinical parameters of glycemic control, HbA1c and CGM data: TIR

    Variation in clinical parameters of glycemic control, HbA1c and CGM data: TIR (time in range)

    Time frame: Day 0 and Biweekly up to 12 weeks

  7. Percentage of patients who complete the study correctly

    Percentage of patients who complete the study correctly by completing all questionnaires

    Time frame: Week 12

  8. Variation in clinical parameters of glycemic control, HbA1c and CGM data: TBR

    Variation in clinical parameters of glycemic control, HbA1c and CGM data: TBR (time below range)

    Time frame: Day 0 and Biweekly up to 12 weeks

  9. Variation in clinical parameters of glycemic control, HbA1c and CGM data: CV

    Variation in clinical parameters of glycemic control, HbA1c and CGM data: CV (Coefficient of Variation)

    Time frame: Day 0 and Biweekly up to 12 weeks

  10. Variation in clinical parameters of glycemic control, HbA1c and CGM data: GRI

    Variation in clinical parameters of glycemic control, HbA1c and CGM data: GRI (Glycemic Risk Index).

    Time frame: Day 0 and Biweekly up to 12 weeks

07

Study locations

1 site
  • Hospital Infantil Universitario Niño Jesús
    Madrid, 28009, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Jan 2025, 5 months.

Of 248 non-industry observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 78. This study's 5 months is below that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Nov 27, 2024
StartActual
Jul 22, 2024
Primary completionActual
Jan 4, 2025
CompletionActual
Jan 4, 2025
Last update
Jun 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06707155
Lead sponsor
Persei Vivarium
Collaborators
Effice Servicios Para la Investigacion S.L.
Responsible party
Sponsor
First posted
Nov 27, 2024
Start date
Jul 22, 2024
Primary completion
Jan 4, 2025
Completion
Jan 4, 2025
Last update
Jun 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion